Premium
Salvage therapy with low‐dose cytosine arabinoside in refractory or relapsed acute non‐lymphocytic leukaemia:
Author(s) -
Jensen M. Krogh,
Johansen P.,
Stentoft J.,
Jensen M. Krogh
Publication year - 1994
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1994.tb00652.x
Subject(s) - medicine , refractory (planetary science) , cytarabine , gastroenterology , chemotherapy , salvage therapy , acute lymphocytic leukemia , surgery , leukemia , lymphoblastic leukemia , physics , astrobiology
Thirteen patients with de novo acute non‐lymphocytic leukaemia (ANLL) refractory to standard chemotherapy for remission induction and 12 patients with ANLL in relapse were treated with low‐dose cytosine arabinoside (LD ara‐C) 10 mg/m 2 subcutaneously every 12 hours for 21 days. Five of 13 patients (38%) and 6 of 12 patients (50%), respectively, obtained a complete remission (CR). Of these, 7 patients subsequently relapsed after 2–76 months, while 4 patients remain in CR after 7–131 months. Compared to standard intensive regimens treatment with LD ara‐C was rather non‐toxic, requiring platelet transfusions and antibiotics in only 6 and 13 cases, respectively. Three patients (12%) died during induction therapy with LD ara‐C; 2 had a cerebral haemorrhage and 1 developed anuria following a staphylococcol septicaemia. In conclusion, therapy with LD ara‐C may be preferable to more intensive and toxic regimens in the treatment of patients with relapsed or refractory ANLL.